# US 2014/0155360 A1 · Calcium Formate for Use as a Dietary Supplement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155360 A1
- Document ID: US20140155360A1
- Status: Published application
- Kind: A1
- Application number: 14/172,423
- Filed: 2014-02-04
- Published: 2014-06-05
- Earliest claimed: 1999-12-22
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Hector F. DeLuca
- Web page: https://patentgrep.com/patent/US20140155360A1

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A23L 33/155: Vitamins A or D
- A23L 33/16: Inorganic salts, minerals or trace elements
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 5/18: of the parathyroid hormones
- A61P 9/08: Vasodilators for multiple indications
- A61P 13/12: of the kidneys
- A61P 21/04: for myasthenia gravis
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.

## Claims

### Claim 1

A method for increasing dietary calcium in an individual, comprising: orally ingesting a quantity of calcium formate sufficient to improve calcium balance or retention.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the quantity of calcium formate is present in an amount sufficient to provide between 10-60 milliequivalents of calcium.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the calcium formate is in tablet form.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the calcium formate is in gelatin capsule form.

### Claim 5 (depends on 1)

The method of claim 1 wherein the calcium formate is orally ingested in a first and second dose, wherein the first dose is before a mealtime and the second dose is after a mealtime.

### Claim 6 (depends on 1)

The method of claim 1 wherein the quantity is a dose of between 0.5 g and 3.0 g per day.

### Claim 7 (depends on 6)

The method of claim 6 wherein the quantity is administered once a day.

### Claim 8 (depends on 1)

The method of claim 1 wherein the calcium formate is combined in a dose with a second, biologically active compound.

### Claim 9 (depends on 8)

The method of claim 8 wherein the second compound is a vitamin D compound.

### Claim 10 (depends on 9)

The method of claim 9 wherein the vitamin D is cholecalciferol.

### Claim 11 (depends on 10)

The method of claim 10 wherein the cholecalciferol is in between 125 IU and 400 IU.

### Claim 12 (depends on 6)

The method of claim 6, wherein the quantity is between 1.0 g and 2.0 g per day.

### Claim 13 (depends on 1)

The method of claim 1 wherein the calcium formate is at least 0.47% calcium in the diet of the individual.